Interventions of Interest:

  • subcutaneous semaglutide (Wegovy®, Novo Nordisk)
  • phentermine/topiramate (Qsymia, Vivus Pharmaceuticals)
  • naltrexone/bupropion (Contrave, Currax Pharma)
  • liraglutide (Saxenda®, Novo Nordisk)

Obesity is an increasingly common chronic condition that is associated with increased risk of chronic diseases such as diabetes, cancer, and heart disease. Individuals who are overweight or those with obesity face considerable social stigma that can make them feel judged, shamed, and ostracized, and can affect interactions with family, friends, and even health professionals. Because obesity often starts in childhood, the stigma can affect social interactions, educational development, relationships, and work throughout life.

For questions, please contact Laura Cianciolo, Program Manager, at

View the Key Stakeholder List.